# A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

> **NCT00673920** · PHASE3 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 314 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Ocrelizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00673920
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04-24
- **Primary completion:** 2009-10-26
- **Final completion:** 2009-10-26
- **Target enrollment:** 314 (ACTUAL)
- **Why stopped:** Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.
- **Last updated:** 2020-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673920, "A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00673920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*